Driven by growing demand for effective drug products, the non-viral / intracellular drug delivery technologies market is likely to grow at 13.8% CAGR, till 2035
Modified tumor-infiltrating lymphocytes (TIL)-based interventions have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects.
Recent Comments